Kiox Pharmaceuticals ApS: Financial statements 2022
CVR: 42886866
Source: annual report 2022, Danish Business Authority
07/12/2021 – 31/12/2022
Kiox Pharmaceuticals ApS (CVR 42886866) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -2,632 and a net result of DKK -2,887. Equity in the 2022 report amounted to DKK 37,113. The solvency ratio was 100%.
- Gross Profit
- DKK -2,632
- Profit/Loss
- DKK -2,887
- Equity
- DKK 37,113
- Total Assets
- DKK 37,113
Official annual report
Keep an eye on Kiox Pharmaceuticals ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Kiox Pharmaceuticals ApS
Kiox Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in Snekkersten, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Mikkel Walmar and Tim Dehli Carstensen. The board consists of Mikkel Walmar (chair), Inge Tarnow and Lars Hellerung Christiansen. The company is owned by HELLERUNG ApS, Titi14 HOLDING ApS and 26c Holding ApS. In 2025, the company reported a gross profit of DKK 120,473 and a net result of DKK -639,537 compared with DKK -1,841,030 the year before. Equity in the 2025 report amounted to DKK -404,366.